NDA 021877 · Sandoz
Arranon
Nelarabine · Intravenous · Nucleoside Metabolic Inhibitor
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Mar 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Oct 28, 2005
Approved uses
2
Original approval plus efficacy supplements
Registered trials
31
6 Phase 3, 3 recruiting
FAERS reports
974
937 serious, 213 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: NEUROLOGIC ADVERSE REACTIONS Severe neurologic adverse reactions have been reported with the use of ARRANON ® . These adverse reactions have included altered mental states including severe somnolence, central nervous system effects including convulsions, and peripheral neuropathy ranging from numbness and paresthesias to motor weakness and paralysis. There have also been reports of adverse reactions associated with demyelination, and ascending peripheral neuropathies similar in appearance to Guillain-Barré syndrome [see Warnings and Precautions (5.1)]. Full recovery from these adverse reactions has not always occurred with cessation of therapy with ARRANON. Monitor frequently for signs and symptoms of neurologic toxicity during treatment with ARRANON. Discontinue ARRANON for neurologic adverse reactions of NCI Common Toxicity Criteria for Adverse Events (CTCAE) Grade 2 or...
What it is approved for
From the label in effect Mar 31, 2025.
ARRANON is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens. ARRANON is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. ( 1 )
Mechanism: Nelarabine is a prodrug of the deoxyguanosine analogue 9-β- D -arabinofuranosylguanine (ara-G), a nucleoside metabolic inhibitor. Nelarabine is demethylated by ADA to ara-G, mono-phosphorylated by deoxyguanosine kinase and deoxycytidine kinase, and subsequently converted to the active 5’-triphosphate, ara-GTP. Accumulation of ara-GTP in leukemic blasts allows for incorporation into deoxyribonucleic acid (DNA), leading to inhibition of DNA synthesis and cell death. Other mechanisms may contribute to the cytotoxic and systemic toxicity of nelarabine.
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 31, 2019 Supplement 10 · Efficacy OrphanLetterLabel
- Oct 28, 2005 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelReviewLetter
1 products under this application
- ARRANON · NELARABINE 250MG/50ML (5MG/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Nelarabine" as an intervention, any sponsor and status, largest first.
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00408005 · 1,895 participants · Start Jan 30, 2007 · Primary completion Sep 30, 2017
Drug: Asparaginase; Cyclophosphamide and 12 more · For: T Acute Lymphoblastic Leukemia; T Lymphoblastic Lymphoma
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 215 sites in all
- Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)Pivotal-lookingNot yet recruiting
Children's Oncology GroupResearch network
NCT07072585 · 1,708 participants (planned) · Start Aug 28, 2026 · Primary completion Sep 1, 2035
Drug: Bortezomib; Calaspargase Pegol and 16 more · For: Stage II T Lymphoblastic Leukemia/Lymphoma; Stage III T Lymphoblastic Leukemia/Lymphoma; Stage IV T Lymphoblastic Leukemia/Lymphoma and 2 more
- Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified TreatmentPivotal-lookingCompleted
Goethe UniversityAcademic, hospital or other
NCT02881086 · 1,023 participants · Start Aug 2016 · Primary completion Dec 2024
Drug: Rituximab; Nelarabine and 15 more · For: Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma
Sites: Frankfurt am Main, Germany
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaPivotal-lookingActive, not recruiting
St. Jude Children's Research HospitalAcademic, hospital or other
NCT03117751 · 790 participants · Start Mar 29, 2017 · Primary completion Sep 30, 2026
Drug: Prednisone; Vincristine and 21 more · For: Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma
Sites: Palo Alto, California; San Diego, California; Peoria, Illinois · 8 sites in all
- Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and AdolescentsPivotal-lookingActive, not recruiting
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT03020030 · 560 participants · Start Mar 3, 2017 · Primary completion Nov 30, 2026
Drug: Pegaspargase; Erwinia asparaginase and 13 more · For: Acute Lymphoblastic Leukemia, Pediatric
Sites: Boston, Massachusetts; New Brunswick, New Jersey; Buffalo, New York · 9 sites in all
- Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old)Status unknown
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT02619630 · 275 participants (planned) · Start Dec 2015 · Primary completion Dec 2020
Drug: nelarabine · For: T-cell Adult Acute Lymphoblastic Leukemia
Sites: Paris, France
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT00501826 · 160 participants (planned) · Start Jul 11, 2007 · Primary completion Oct 31, 2028
Drug: Cyclophosphamide; Cytarabine and 9 more · For: T Acute Lymphoblastic Leukemia; T Lymphoblastic Lymphoma
Sites: Houston, Texas
National Cancer Institute (NCI)NIH
NCT00002970 · 148 participants · Start Jun 1997 · Primary completion Jan 2005
Drug: nelarabine; methotrexate and 2 more · For: Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Lymphoblastic Lymphoma; T-cell Childhood Acute Lymphoblastic Leukemia
Sites: Arcadia, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- febrile neutropenia76
- drug ineffective67
- neuropathy peripheral63
- neurotoxicity61
- peripheral sensory neuropathy56
- sepsis56
- muscular weakness55
- off label use53
- myelopathy52
- neutropenia52
- guillain-barre syndrome42
- thrombocytopenia41
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 10 |
| 2007 | 13 |
| 2008 | 17 |
| 2009 | 24 |
| 2010 | 26 |
| 2011 | 26 |
| 2012 | 27 |
| 2013 | 73 |
| 2014 | 52 |
| 2015 | 39 |
| 2016 | 48 |
| 2017 | 64 |
| 2018 | 56 |
| 2019 | 29 |
| 2020 | 39 |
| 2021 | 35 |
| 2022 | 98 |
| 2023 | 77 |
| 2024 | 68 |
| 2025 | 116 |
| 2026 | 37 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Arranon* (Nelarabine*) · HCPCS J9261
2024 spending
$89K
Beneficiaries
n/a
30 claims
Per beneficiary
n/a
2024 ASP limit $89.69 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $541,497 |
| 2021 | $563,199 |
| 2022 | $403,824 |
| 2023 | $374,025 |
| 2024 | $89,435 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.
Dunsmore KP, Winter SS, Devidas M, et al. · J Clin Oncol 2020 · Clinical Trial, Phase III, Randomized Controlled Trial
- Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma.
Ravandi F, Senapati J, Jain N, et al. · Leukemia 2024 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- The efficacy and safety of nelarabine in relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
Shakeel L, Khaliq N, Shaukat A, et al. · Ann Hematol 2025 · Systematic Review, Meta-Analysis
- Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action.
Hormann FM, Rudd SG · Leukemia 2025 · Systematic Review, Research Support, Non-U.S. Gov't
- [Treatment strategy for T-cell acute lymphoblastic leukemia in children].
Sato A · Rinsho Ketsueki 2022 · Clinical Trial
- Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
Sato A, Hatta Y, Imai C, et al. · Lancet Haematol 2023 · Randomized Controlled Trial, Clinical Trial, Phase II
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.